Melflufen
What the Research Actually Shows
Human: 2 studies, 3 groups · Animal: 0 · In Vitro: 0
The peptide-drug conjugate that shrank tumors but shortened lives — the rise and fall of the first withdrawn peptide cancer drug
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Melflufen was an FDA-approved peptide-drug conjugate for a blood cancer called multiple myeloma. It used a small peptide as a Trojan horse to sneak a cancer-killing chemical inside tumor cells. In early studies, it shrank tumors in nearly 30% of patients who had no other treatment options — impressive enough for FDA approval in 2021. But a larger follow-up trial revealed something devastating: patients on melflufen died sooner than those on a standard drug, despite their tumors shrinking. The reason appears to be severe bone marrow damage that left patients unable to fight infections or receive further treatment. Melflufen was voluntarily pulled from the market in 2024. It remains the clearest example in oncology of why tumor shrinkage doesn't always mean patients do better.
Melflufen — marketed briefly as Pepaxto — represents the most dramatic rise and fall in recent peptide oncology. It was a peptide-drug conjugate designed to exploit a biological vulnerability: tumor cells overexpress aminopeptidase enzymes that normal cells express at lower levels. By linking the alkylating agent melphalan to a lipophilic dipeptide, melflufen could cross cell membranes rapidly, get cleaved by intracellular aminopeptidases, and release melphalan at concentrations up to 50-fold higher inside tumor cells than achievable with systemic melphalan alone.
The HORIZON trial (N=157) showed a 29% objective response rate in triple-class refractory multiple myeloma — patients who had exhausted all standard therapies. This was clinically meaningful in a population with a median of five prior treatment lines, and the FDA granted accelerated approval in February 2021 (PMID 33529983).
Then OCEAN happened. The confirmatory Phase III trial (N=495) randomized melflufen against pomalidomide and delivered a result that shook the oncology community: melflufen met the progression-free survival endpoint (HR 0.79) but showed worse overall survival (HR 1.104, PMID 35839435). Patients on melflufen lived shorter lives than those on the comparator — despite their tumors progressing more slowly. Oncopeptides AB voluntarily withdrew Pepaxto from the US market in February 2024.
Melflufen's story is a cautionary tale about the difference between a surrogate endpoint and what actually matters. It also illustrates that the peptide-drug conjugate concept itself is not flawed — the failure was melflufen-specific, driven by toxicity severity rather than a fundamental problem with using peptides to deliver cytotoxic payloads.
In This Article
Quick Facts: Melflufen at a Glance
Type
Peptide-drug conjugate (PDC): dipeptide carrier linked to alkylating agent melphalan
Also Known As
Melphalan flufenamide, Pepaxto, melflufen hydrochloride
Generic Name
Melphalan flufenamide hydrochloride
Brand Name
Pepaxto (WITHDRAWN from US market February 2024)
Related Compounds
Melphalan (the parent alkylating agent, FDA-approved for myeloma since 1964), other PDCs in development across oncology
WADA Status
Not on WADA Prohibited Lists
Molecular Weight
~499 Da
Peptide Sequence
L-melphalanyl-p-L-fluorophenylalanine ethyl ester (dipeptide conjugate, not a traditional peptide chain)
Endogenous Origin
No endogenous counterpart. Synthetic dipeptide designed as a lipophilic Trojan horse for intracellular melphalan delivery
Primary Molecular Function
Lipophilic cell entry → intracellular aminopeptidase (CD13) cleavage → release of alkylating melphalan at high intracellular concentrations → DNA crosslinking → cell death
Active Fragment
The active payload is melphalan (an alkylating agent). The dipeptide carrier enables rapid cell entry and intracellular activation — the peptide is the delivery system, not the drug
Half-Life
Rapid intracellular conversion: melflufen is cleaved within minutes of cell entry. Plasma half-life of released melphalan ~90 minutes
Clinical Programs
HORIZON Phase II (basis for accelerated approval), OCEAN Phase III (confirmatory trial — led to withdrawal), O-12-M1 Phase 1/2 (dose-finding)
Route
Intravenous infusion over 30 minutes in hospital/clinic setting
FDA Status
Accelerated approval February 2021. VOLUNTARILY WITHDRAWN February 2024 after OCEAN showed worse overall survival
Community Interest
No community use. Melflufen was a hospital-administered IV chemotherapy drug, now withdrawn from the market
Evidence Tier
2 Clinical Trials
Verdict
Thin Ice
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Melflufen?
Pronunciation: MEL-floo-fen
Melphalan is one of the oldest drugs in cancer treatment — an alkylating agent first approved for multiple myeloma in 1964. It works by crosslinking DNA strands inside cancer cells, preventing them from dividing. It is effective, but its usefulness is limited by the same problem that plagues most chemotherapy: it kills healthy cells almost as readily as tumor cells. The dose you can give is constrained by the dose the patient can survive.
Melflufen was designed to break that constraint. Its creators at Oncopeptides AB asked a simple question: what if you could get melphalan inside tumor cells at much higher concentrations than normal cells? The answer was a peptide-drug conjugate — a lipophilic dipeptide chemically linked to melphalan that exploits a specific enzyme difference between tumor and normal cells.
The key enzyme is aminopeptidase N (CD13), which is overexpressed in many cancer types including multiple myeloma. Melflufen enters cells rapidly — roughly 20 times faster than free melphalan — because of its lipophilic dipeptide carrier. Once inside, intracellular aminopeptidases cleave the peptide bond and release free melphalan directly inside the cell at concentrations up to 50-fold higher than achievable with systemic melphalan. In theory, this means more drug in the tumor and less drug everywhere else.
In practice, the theory broke down. The selectivity was not sufficient to prevent devastating bone marrow toxicity, and the consequences of that toxicity proved fatal.
PLAIN ENGLISH
Melflufen was designed as a smarter version of an old cancer drug. It used a small peptide to sneak the drug inside cancer cells, where enzymes would release it at very high concentrations. The idea was to concentrate the killing power inside tumors while sparing normal tissue. The concept was sound, but the execution — at least with this particular drug — caused severe bone marrow damage that ultimately shortened patients' lives.
Origins and Discovery
Melflufen was developed by Oncopeptides AB, a Swedish pharmaceutical company founded in 2000 specifically to develop peptide-drug conjugates for oncology. The company's founding insight was that aminopeptidases — enzymes that cleave peptide bonds from the N-terminus of proteins — are overexpressed in many cancer types and could be exploited as intracellular drug-release triggers.
The choice of melphalan as the cytotoxic payload was deliberate: melphalan had decades of proven efficacy in multiple myeloma, and its toxicity profile was well-characterized. The question was whether a peptide-based delivery strategy could improve its therapeutic index — the ratio between the dose that treats disease and the dose that harms the patient.
Preclinical data was encouraging. In cell-based assays, melflufen achieved intracellular melphalan concentrations 50-fold higher than equimolar doses of free melphalan. In animal models, melflufen showed enhanced antitumor activity with a suggestion of improved selectivity. These results justified clinical development, and Oncopeptides advanced melflufen through Phase 1/2, Phase 2 (HORIZON), and Phase 3 (OCEAN) trials between 2013 and 2022.
The timeline from accelerated approval (February 2021) to voluntary withdrawal (February 2024) was three years — a trajectory that has become a reference case for discussions about the accelerated approval pathway in oncology.
Mechanism of Action
The Peptide-Drug Conjugate Strategy
Melflufen's mechanism operates in four steps:
1. Rapid cell entry: The lipophilic dipeptide carrier enables melflufen to cross cell membranes approximately 20 times faster than free melphalan. This is passive diffusion — no receptor binding is required. The lipophilicity of the fluorophenylalanine component drives membrane permeation.
2. Intracellular activation: Once inside the cell, aminopeptidases (particularly aminopeptidase N/CD13) cleave the peptide bond between the dipeptide carrier and melphalan. Tumor cells have higher aminopeptidase activity than most normal cells, creating a theoretical selectivity window.
3. Intracellular trapping: Free melphalan released inside the cell is hydrophilic — it cannot easily cross back out through the cell membrane. This traps the drug inside the cell at high concentrations — the "Trojan horse" effect.
4. DNA crosslinking: The intracellular melphalan forms covalent bonds between DNA strands (interstrand crosslinks), preventing DNA replication and triggering apoptosis (PMID 29085107).
PLAIN ENGLISH
Melflufen gets inside cells fast because of its fatty peptide coating. Once inside, the cell's own enzymes strip off the coating and release the cancer-killing drug. Because the released drug can't get back out of the cell, it accumulates to very high concentrations. Cancer cells have more of the stripping enzyme, so they accumulate more drug — at least in theory.
Where the Selectivity Failed
The theoretical selectivity window — more aminopeptidase in tumor cells, therefore more melphalan release in tumor cells — was insufficient to prevent severe bone marrow toxicity. Hematopoietic stem and progenitor cells also express aminopeptidases and are highly sensitive to alkylating damage. The resulting cytopenias were deeper and more prolonged than those seen with standard melphalan, which paradoxically narrowed rather than widened the therapeutic index.
Key Research Areas and Studies
HORIZON — The Rise (PMID 33529983)
The HORIZON trial was the basis for melflufen's accelerated approval and initially appeared to validate the PDC concept.
Design: Single-arm Phase 2. 157 enrolled, 97 efficacy-evaluable. Triple-class refractory relapsed/refractory multiple myeloma — patients who had failed proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.
Results: - Objective response rate: 29.1% - Including 1 stringent complete response, 5 very good partial responses - Median PFS: 4.2 months - Median OS: 11.6 months - In a population with no standard therapy options, any meaningful response rate was clinically relevant
Context: Accelerated approval requires a surrogate endpoint (here, ORR) reasonably likely to predict clinical benefit, with a confirmatory trial to verify that prediction. HORIZON met the surrogate; OCEAN was the confirmatory test.
PLAIN ENGLISH
HORIZON tested melflufen in patients who had run out of options. Nearly 30% saw their cancer shrink — enough for the FDA to grant conditional approval while a larger, more rigorous trial was conducted.
OCEAN — The Fall (PMID 35839435)
OCEAN was the confirmatory trial that unraveled melflufen's approval.
Design: Randomized, open-label Phase III. 495 patients with relapsed/refractory multiple myeloma, 2–4 prior lines of therapy. Melflufen 40 mg IV + dexamethasone vs. pomalidomide 4 mg oral + dexamethasone.
Results: - PFS: HR 0.79 (met primary endpoint — melflufen delayed progression more than pomalidomide) - OS: HR 1.104 (detrimental — melflufen patients died sooner than pomalidomide patients) - The survival paradox: better PFS but worse OS
The explanation: Melflufen's severe myelosuppression had two lethal consequences. First, profound neutropenia led to higher rates of fatal infections (pneumonia, sepsis — exacerbated by COVID-19 during the enrollment period). Second, prolonged cytopenias prevented patients from receiving subsequent lines of therapy — in a disease where sequential treatment is essential for survival.
PLAIN ENGLISH
The bigger trial answered the critical question: does shrinking tumors actually help patients live longer? For melflufen, the answer was no. Patients' tumors grew more slowly on melflufen, but they died sooner — mainly because the drug so severely damaged their bone marrow that they couldn't fight infections or receive further cancer treatment.
The Renal Impairment Signal
Post-hoc analysis of OCEAN revealed that the survival deficit was concentrated among patients with impaired renal function (eGFR <45 mL/min). In this subgroup, melflufen's toxicity was disproportionately severe. This suggests that renal clearance plays a role in limiting melphalan exposure — when kidney function is impaired, released melphalan accumulates systemically rather than being cleared, amplifying bone marrow toxicity.
The Accelerated Approval Lesson
Melflufen's trajectory has become a teaching case for regulatory science. The accelerated approval pathway was designed for situations where a surrogate endpoint (like tumor shrinkage) reasonably predicts clinical benefit — allowing patients with serious conditions to access drugs sooner while confirmatory trials continue.
The assumption embedded in melflufen's approval was that shrinking tumors in triple-class refractory myeloma would translate to longer survival. OCEAN showed this assumption was wrong — not because the drug didn't shrink tumors (it did), but because the toxicity that came with the shrinkage was worse than the disease itself.
This raises fundamental questions about accelerated approval: - Single-arm ORR data cannot reveal whether a drug does more good than harm — it can only show that tumors shrink. You need a comparator arm to see the full picture. - PFS and OS can diverge when a drug's toxicity prevents sequential therapy — a reality in myeloma, where patients cycle through multiple treatment lines. - The speed of accelerated approval creates a window during which patients receive a drug that may ultimately prove harmful.
These are not criticisms of the regulatory system — accelerated approval saves lives when the gamble pays off. Melflufen is what happens when it doesn't.
PLAIN ENGLISH
The FDA approved melflufen quickly because tumors were shrinking. But the bigger trial showed that shrinking tumors isn't always enough — if the drug causes severe side effects that prevent further treatment, patients can end up worse off. That's the cautionary lesson.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Melflufen shrinks tumors in refractory myeloma"” | HORIZON: 29% ORR in triple-class refractory patients. OCEAN: met PFS endpoint (HR 0.79). Tumor shrinkage is documented. | Supported |
| “"Melflufen delivers melphalan selectively to tumor cells"” | Preclinical data shows higher intracellular melphalan in aminopeptidase-overexpressing cells. Clinical data shows severe bone marrow toxicity — selectivity was insufficient to spare hematopoietic cells. | Mixed Evidence |
| “"Melflufen helps patients live longer"” | OCEAN OS HR 1.104 — patients on melflufen died sooner than those on pomalidomide. This is the finding that led to market withdrawal. PMID 35839435 | Unsupported |
| “"PDCs are a failed concept"” | Melflufen failed because of drug-specific toxicity (myelosuppression severity), not a fundamental flaw in the PDC strategy. Other PDCs continue in development. | Unsupported |
| “"Melflufen is safer than standard melphalan"” | Grade 3/4 neutropenia (79%) and thrombocytopenia (76%) in HORIZON — severe myelosuppression was the dominant toxicity. Not demonstrably safer than standard melphalan regimens. | Unsupported |
| “"Accelerated approval means the drug is proven effective"” | Accelerated approval is based on surrogate endpoints (ORR) with a confirmatory trial required. OCEAN was the confirmatory trial, and it failed the OS endpoint. | Unsupported |
| “"Melflufen was withdrawn because it didn't work"” | It did shrink tumors (met PFS). It was withdrawn because it shortened overall survival — the toxicity outweighed the antitumor benefit. | Mixed Evidence |
| “"Melflufen is still available somewhere"” | Pepaxto was voluntarily withdrawn from the US market in February 2024. It is not commercially available. Oncopeptides filed for insolvency. | Unsupported |
| “"All alkylating agents have this problem"” | Other melphalan-based regimens (high-dose melphalan with stem cell rescue) remain standard of care in myeloma. The problem was melflufen-specific intensity of bone marrow damage. | Unsupported |
| “"Melflufen failed because of COVID-19"” | COVID-19 infections during OCEAN enrollment contributed to fatal infectious AEs in the melflufen arm, but the survival deficit persisted after adjusting for pandemic effects. COVID was a confounder, not the sole cause. | Mixed Evidence |
| “"Tumor shrinkage always means the drug is helping"” | Melflufen is the definitive counterexample. PFS improved (HR 0.79) while OS worsened (HR 1.104). Surrogate endpoints can mislead. | Unsupported |
| “"The PDC approach should be abandoned"” | Multiple PDCs remain in clinical development. The principle — peptide-targeted intracellular drug delivery — is mechanistically sound. Melflufen's failure was one drug, not one concept. | Unsupported |
The Human Evidence Landscape
HORIZON (Richardson et al., 2021, PMID 33529983)
Design: Single-arm Phase 2 Population: 157 enrolled (97 efficacy-evaluable), triple-class refractory relapsed/refractory multiple myeloma. Median 5 prior lines of therapy. Intervention: Melflufen 40 mg IV Day 1 + dexamethasone 40 mg weekly, 28-day cycles Key finding: ORR 29.1%. Median PFS 4.2 months. Median OS 11.6 months. Limitations: Single-arm — no comparator to reveal relative benefit-risk. Surrogate endpoint (ORR) — could not assess OS impact. Small efficacy-evaluable population (97 patients).
OCEAN (Schjesvold et al., 2022, PMID 35839435)
Design: Randomized, open-label Phase III Population: 495 patients, relapsed/refractory multiple myeloma, 2–4 prior lines Intervention: Melflufen 40 mg IV + dex vs. pomalidomide 4 mg oral + dex Key finding: PFS HR 0.79 (met primary endpoint). OS HR 1.104 (detrimental — worse survival with melflufen). Limitations: Open-label (no blinding). COVID-19 pandemic overlapped enrollment, contributing to infectious deaths. Renal impairment subgroup drove disproportionate toxicity. The PFS/OS divergence raised fundamental questions about the relevance of PFS as a surrogate for OS in this population.
O-12-M1 (Phase 1/2 Dose-Finding)
Design: Phase 1/2 dose-escalation and expansion Population: Relapsed/refractory multiple myeloma patients Key finding: Established 40 mg IV every 28 days as recommended Phase 2 dose. Dose-limiting toxicity was myelosuppression (neutropenia, thrombocytopenia). Limitations: Early-phase, dose-finding. Not designed for efficacy conclusions.
Safety, Risks, and Limitations
Critical Safety Profile — The Reason for Withdrawal
Melflufen's safety profile was the direct cause of its market withdrawal. The toxicity was severe, prolonged, and in some cases fatal:
Myelosuppression (dominant toxicity): Grade 3/4 neutropenia in 79% of HORIZON patients. Grade 3/4 thrombocytopenia in 76%. Grade 3/4 anemia in 64%. These rates are among the highest for any approved myeloma therapy. The cytopenias were deep and slow to recover.
CRITICAL DISCLAIMER
Melflufen caused bone marrow damage so severe that many patients could not receive further lines of cancer treatment after stopping it. In a disease where sequential therapy is essential for survival, this toxicity effectively removed patients' remaining treatment options.
Fatal infections: In OCEAN, the melflufen arm experienced higher rates of fatal infections — pneumonia, neutropenic sepsis, and COVID-19 — than the pomalidomide arm. Profound neutropenia left patients unable to fight common infections.
Renal impairment risk: Patients with eGFR <45 mL/min experienced disproportionately severe toxicity. Post-hoc analysis identified this subgroup as a primary driver of the survival deficit.
Hepatotoxicity: Transaminase elevations were reported but were not the primary safety concern.
Secondary malignancy: As an alkylating agent, cumulative melphalan exposure carries a theoretical risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Few patients received enough cycles for this to manifest.
PLAIN ENGLISH
Melflufen was pulled from the market because it was too toxic. It severely damaged the bone marrow, leaving patients unable to fight infections or receive additional cancer treatments. Patients on melflufen died sooner than those on a standard drug — the opposite of what any cancer treatment is supposed to do.
Legal and Regulatory Status
Regulatory Timeline
- February 2021: FDA accelerated approval based on HORIZON ORR data (triple-class refractory myeloma)
- July 2021: FDA issued safety alert regarding higher death rate in OCEAN interim analysis
- October 2021: Oncopeptides temporarily suspended marketing while OCEAN data matured
- February 2024: Voluntary market withdrawal after final OCEAN OS analysis confirmed detrimental signal
- Oncopeptides AB: Filed for restructuring/insolvency. The company's primary asset was Pepaxto.
Current Status
Pepaxto is not commercially available anywhere. The FDA approval has been voluntarily withdrawn. Melflufen is not available from pharmacies, compounding sources, or any other channel.
The Accelerated Approval Debate
Melflufen's trajectory has intensified regulatory scrutiny of the accelerated approval pathway. It is cited in FDA advisory committee discussions about whether single-arm ORR studies provide sufficient evidence for conditional approval, and whether PFS/OS divergence should be a mandatory withdrawal trigger.
Research Protocols and Formulation Considerations
Formulation
Melflufen was supplied as a lyophilized powder for IV infusion, reconstituted and administered over 30 minutes. The dipeptide conjugate is inherently unstable in aqueous solution — the same aminopeptidase-mediated cleavage that occurs intracellularly also occurs in plasma, creating a pharmacokinetic challenge of delivering intact conjugate to tumor cells before systemic cleavage releases melphalan into the general circulation.
The Therapeutic Index Problem
The PDC concept assumes that intracellular drug release exceeds extracellular release by a sufficient margin to create tumor selectivity. For melflufen, preclinical data supported this assumption (50-fold higher intracellular melphalan). Clinical data showed that the margin was insufficient to protect bone marrow progenitors — cells that also express aminopeptidases and are exquisitely sensitive to alkylating damage.
Dosing in Published Research
The following table summarizes dosing protocols for Melflufen as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Clinical Dosing (Now Withdrawn)
| Parameter | Value |
|---|---|
| Dose | 40 mg IV over 30 minutes |
| Schedule | Day 1 of each 28-day cycle |
| Combination | Dexamethasone 40 mg orally weekly |
| Setting | Hospital/clinic with IV infusion capability |
| Monitoring | CBC with differential before each cycle. Dose delay if ANC <1.0 or platelets <75 |
| Renal caution | Avoid in patients with eGFR <45 mL/min (post-hoc safety signal from OCEAN) |
PLAIN ENGLISH
Melflufen was given as a 30-minute IV drip once a month, combined with a steroid (dexamethasone). Blood counts were checked before each dose because the drug severely suppresses bone marrow. This regimen is no longer available — the drug was withdrawn from the market.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Melflufen combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Melflufen with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target/Receptor | Landmark Trial | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Octreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/5 agonist → antisecretory + antiproliferative | SSTR2, SSTR5 | PROMID (N=85, TTP HR 0.34) | Phase III RCT; 30+ years clinical use | Approved 1988 (acromegaly, carcinoid, GEP-NETs) | Not prohibited | Gallstones (15–30%); glucose metabolism effects |
| Lanreotide | Cyclic octapeptide SSA (8 aa, disulfide) | Tier 1 — Approved Drug | Strong Foundation | SSTR2/3/5 agonist → antiproliferative in nonfunctioning NETs | SSTR2, SSTR3, SSTR5 | CLARINET (N=204, PFS HR 0.47) | Phase III RCT; 15+ years post-approval | Approved 2007 (acromegaly); 2014 (GEP-NETs) | Not prohibited | Same class as octreotide; gallstones; glucose effects |
| Lutathera | Radiolabeled peptide (¹⁷⁷Lu-DOTATATE) | Tier 1 — Approved Drug | Strong Foundation | SSTR2-targeted PRRT → intracellular beta-radiation → DNA damage | SSTR2 | NETTER-1 (N=229, PFS HR 0.21) | Phase III RCT + 504-pt registry | Approved January 2018 (SSTR+ GEP-NETs) | Not prohibited | Myelosuppression; MDS/AML risk (~2%); requires nuclear medicine facility |
| Motixafortide | Cyclic peptide (14 aa) | Tier 2 — Clinical Trials | Reasonable Bet | CXCR4 antagonist → stem cell mobilization + tumor immune sensitization | CXCR4 | GENESIS (N=122, 92.5% vs. 26.2% mobilization) | Phase III + Phase 2a (N=199 total) | Not approved (Phase 3 complete) | Not prohibited | No FDA approval yet; competes with approved plerixafor |
| Melflufen | Peptide-drug conjugate (dipeptide-melphalan) | Tier 2 — Clinical Trials | Thin Ice | Aminopeptidase-activated intracellular melphalan release → DNA crosslinking | Aminopeptidase N (CD13) | OCEAN (N=495, PFS HR 0.79 but OS HR 1.104) | Phase III RCT (N=652 total) | Approved Feb 2021; WITHDRAWN Feb 2024 | Not prohibited | Worse OS than comparator; severe myelosuppression; market withdrawal |
| Cilengitide | Cyclic RGD pentapeptide (5 aa) | Tier 2 — Clinical Trials | Thin Ice | αvβ3/αvβ5 integrin antagonist → antiangiogenic | αvβ3, αvβ5 integrins | CENTRIC (N=545, OS HR 1.02) | Phase III RCT (N=891 total) | Not approved; development discontinued | Not prohibited | Definitive Phase III failure (HR 1.02); development abandoned |
style="color:#0F4C5C;font-size:28px;font-weight:700;margin:48px 0 16px 0;line-height:1.2">Frequently Asked Questions
What was melflufen (Pepaxto)?
Why was Pepaxto withdrawn from the market?
How did the peptide-drug conjugate concept work?
If tumors were shrinking, why did patients die sooner?
Is melflufen still available anywhere?
Does melflufen's failure mean peptide-drug conjugates don't work?
What is the difference between accelerated approval and full approval?
What lessons does melflufen teach about cancer drug development?
Was the problem with melphalan or with the peptide delivery?
Are there other treatments for triple-class refractory myeloma?
Could melflufen be reformulated or improved?
What does this mean for patients who were on Pepaxto?
Summary of Key Findings
Melflufen is the most instructive failure in peptide oncology. A peptide-drug conjugate that achieved FDA accelerated approval based on meaningful tumor responses in patients with no other options — and then was withdrawn three years later because a larger trial showed it shortened patients' lives.
The HORIZON ORR (29% in triple-class refractory myeloma) was real. The OCEAN PFS benefit (HR 0.79) was real. But the OCEAN OS deficit (HR 1.104) was also real — and in oncology, overall survival is the endpoint that matters most. Severe myelosuppression led to fatal infections and prevented sequential therapy, negating the antitumor benefit.
Melflufen's legacy is educational: it is the clearest demonstration that tumor shrinkage and patient benefit are not synonymous, and that the peptide-drug conjugate concept must solve the selectivity problem to succeed.
PLAIN ENGLISH
Melflufen was a cancer drug that used a peptide to deliver a poison directly inside tumor cells. It worked — tumors shrank. But it damaged the bone marrow so badly that patients died sooner than those on a standard drug. It was approved in 2021 and pulled from the market in 2024. The lesson: shrinking a tumor doesn't help if the treatment kills you faster than the disease.
Verdict Recapitulation
Melflufen has Phase III data from hundreds of patients — it earned Tier 2 on the basis of that clinical development program. But the direction of that evidence is negative. OCEAN showed worse overall survival, and the drug has been withdrawn. Thin Ice — the evidence exists, but it points in the wrong direction.
For readers considering Melflufen, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Melflufen
Further Reading and Resources
If you want to go deeper on Melflufen, the evidence landscape for cancer & oncology peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Cancer & Oncology Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Melflufen — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Richardson PG, Oriol A, Larocca A, et al. (2021). "Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma." Journal of Clinical Oncology, 39(7), 757–767. PMID 33529983
- Schjesvold FH, Dimopoulos MA, Beksac M, et al. (2022). "OCEAN: a randomized Phase III study of melflufen/dexamethasone (dex) vs pomalidomide/dex in relapsed refractory multiple myeloma (RRMM)." Journal of Clinical Oncology, 40(suppl 16), 8004. PMID 35839435
- Wickström M, Nygren P, Larsson R, et al. (2017). "Melflufen — a peptidase-potentiated alkylating agent in clinical trials." Oncotarget, 8(39), 66641–66655. PMID 29085107
- Chauhan D, Ray A, Viber B, et al. (2013). "In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells." Clinical Cancer Research, 19(11), 3019–3031. PMID 23620408
- US FDA. (2021). Pepaxto (melphalan flufenamide) Prescribing Information. Silver Spring, MD
- Oncopeptides AB. (2024). Voluntary withdrawal of Pepaxto from the US market. Press release
DISCLAIMER
Melflufen is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.